Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant ascites
- Focus Adverse reactions
- 20 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 May 2013 New trial record